Subcutaneous · GIP agonist
ZP6590
1 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
1
Ongoing
1
Recruiting
1
Completed
0
Sites
1
Countries
1
Endpoints
22
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Early Phase 1
1
Trials by status
Recruiting
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
22
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07721597A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity | ZP6590 Healthy volunteers, Obesity / overweight | BMI 20-29.9 | Early Ph 1 | Recruiting | 1 | Sep 2027 | - |
Showing 1-1 of 1 trials